Reviewed by John M. Grohol, Psy.D. on May 27, 2011
University of Montreal researchers say that the drug metyrapone reduces the brain’s ability to re-record the negative emotions associated with painful memories. In other words, bad memories are effectively blocked from being recalled or remembered.
The team’s study challenges the theory that memories cannot be modified once they are stored in the brain.
“Metyrapone is a drug that significantly decreases the levels of cortisol, a stress hormone that is involved in memory recall,” explained lead author Marie-France Marin, a doctoral student.
Manipulating cortisol close to the time of forming new memories can decrease the negative emotions that may be associated with them, the researchers said.
“The results show that when we decrease stress hormone levels at the time of recall of a negative event, we can impair the memory for this negative event with a long-lasting effect,” said Sonia Lupien, Ph.D., who directed the research.
Thirty-three men participated in the study, which involved learning a story composed of neutral and negative events.
Three days later, they were divided into three groups – participants in the first group received a single dose of metyrapone and a second group received a double dose. The third group received a placebo.
Group participants were then asked to remember the story. Then, in fours days after the medication had cleared from the body, individual memory performance was reevaluated.
“We found that the men in the group who received two doses of metyrapone were impaired when retrieving the negative events of the story, while they showed no impairment recalling the neutral parts of the story,” Marin said.
“We were surprised that the decreased memory of negative information was still present once cortisol levels had returned to normal.”
The research offers hope to people suffering from syndromes such as post-traumatic stress disorder.
“Our findings may help people deal with traumatic events by offering them the opportunity to ‘write-over’ the emotional part of their memories during therapy,” Marin said. One major hurdle, however, is the fact that metyrapone is no longer commercially produced.
Despite the inavailabilty of the medication, the proof in concept may spur future clinical studies.
“Other drugs also decrease cortisol levels, and further studies with these compounds will enable us to gain a better understanding of the brain mechanisms involved in the modulation of negative memories.”
Source: University of Montreal